Sigma Planning’s ImmunityBio IBRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$190K Buy
20,115
+1,100
+6% +$8.79K ﹤0.01% 1264
2026
Q2
$166K Buy
19,015
+1,300
+7% +$9.8K ﹤0.01% 1360
2026
Q1
$136K Buy
17,715
+715
+4% +$4.9K ﹤0.01% 1268
2025
Q4
$33.7K Hold
17,000
– – ﹤0.01% 1286
2025
Q3
$41.8K Hold
17,000
– – ﹤0.01% 1280
2025
Q2
$44.9K Hold
17,000
– – ﹤0.01% 1233
2025
Q1
$51.2K Hold
17,000
– – ﹤0.01% 1183
2024
Q4
$43.5K Hold
17,000
– – ﹤0.01% 1149
2024
Q3
$63.2K Sell
17,000
-795
-4% -$3.68K ﹤0.01% 1183
2024
Q2
$112K Buy
17,795
+4,875
+38% +$32.1K ﹤0.01% 1132
2024
Q1
$69.4K Buy
+12,920
New +$58.5K ﹤0.01% 1189
2023
Q4
– Sell
-11,050
Closed -$18.7K – 1005
2023
Q3
$18.7K Hold
11,050
– – ﹤0.01% 1180
2023
Q2
$30.7K Hold
11,050
– – ﹤0.01% 1180
2023
Q1
$20.1K Hold
11,050
– – ﹤0.01% 1280
2022
Q4
$56K Buy
11,050
+300
+3% +$1.65K ﹤0.01% 1226
2022
Q3
$53K Hold
10,750
– – ﹤0.01% 1216
2022
Q2
$40K Buy
10,750
+300
+3% +$1.2K ﹤0.01% 1257
2022
Q1
$59K Buy
+10,450
New +$64.1K ﹤0.01% 1333

Other funds holding IBRX

Sigma Planning's IBRX Position: Q3 2026 in Review

Sigma Planning increased its ImmunityBio (IBRX) stake by 5.8% in Q3 2026, buying an estimated $8.79K and bringing the position to 20,115 shares worth $190K. The position accounts for ﹤0.01% of the portfolio, ranked #1264.

Sigma Planning first reported a position in IBRX in Q1 2022 and has held it in 18 quarters since. 321 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

  • Sigma Planning held 20,115 shares of ImmunityBio worth $190K as of Q3 2026.
  • Sigma Planning bought 1,100 ImmunityBio shares in Q3 2026, an estimated $8.79K.
  • ImmunityBio made up ﹤0.01% of Sigma Planning's portfolio in Q3 2026, its #1264 holding.
  • Sigma Planning first reported a position in ImmunityBio in Q1 2022 and has held it in 18 quarters since.
  • 321 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on Sigma Planning's 13F filing for Q3 2026, filed 23 Oct 2026.